New treatment destroys head and neck cancer tumours in trial

Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study finds

A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered.

In a landmark trial, a cocktail of immunotherapy medications harnessed patients’ immune systems to kill their own cancer cells and prompted “a positive trend in survival”, according to researchers at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.

One patient, who was expected to die four years ago, told the Guardian of the “amazing” moment nurses called him weeks after he joined the study to say his tumour had “completely disappeared”. The 77-year-old grandfather is now cancer-free and spent last week on a cruise with his wife.

Scientists found the combination of nivolumab and ipilimumab medications led to a reduction in the size of tumours in terminally ill head and neck cancer patients. In some, their cancer vanished altogether, with doctors stunned to find no detectable sign of disease.

Combining the two immunotherapy drugs could prove an effective new weapon against several forms of advanced cancer, experts believe. Results from other trials of the drug combination have previously suggested similar benefits for terminally ill kidney, skin and bowel cancer patients.

As well as boosting the long-term survival chances of patients, scientists said, the immunotherapy treatment also triggered far fewer side-effects compared with the often gruelling nature of “extreme” chemotherapy, which is the standard treatment offered to many patients with advanced cancer.

The results from the phase 3 trial, involving almost 1,000 dying head and neck cancer patients, were early and not statistically significant but were still “clinically meaningful”, the ICR said, with some patients living months or years longer and suffering fewer side effects.

“These are promising results,” Prof Kristian Helin, the ICR chief executive, told the Guardian. “Immunotherapies are kinder, smarter treatments that can bring significant benefits to patients.”

About 12,000 people in the UK are diagnosed with head and neck cancer every year and many will be diagnosed at advanced stages. There is an urgent need for better, kinder treatments for these patients that can keep them alive longer than the current standard of care.

When Barry Ambrose, 77, from Bury St Edmunds, was diagnosed with throat cancer in 2017, he was told that it had already spread to his lungs – and that hospital palliative care was his only option.

But in a turn of events that saved his life, Ambrose was offered the chance to join the new study. “When I was told about the trial … I didn’t hesitate to join – what did I have to lose? It turned out to be a lifeline.

“Although I had to make biweekly trips from Suffolk to the hospital for the treatment, I had virtually no side-effects and was able to carry on as normal doing the things I love: sailing, cycling, and spending time with my family.”

Within about eight weeks of starting the treatment, scans revealed the tumour in his throat had been eradicated.

“When the research nurses called to tell me that, after two months, the tumour in my throat had completely disappeared, it was an amazing moment,” said Ambrose. “While there was still disease in my lungs at that point, the effect was staggering.”

He later underwent chemotherapy, followed by surgery. He currently has no evidence of disease.

“The treatment I’ve received at the Royal Marsden has been second to none and I’m so fortunate they’ve continued to find treatment that works for me – they’re the gift that keeps on giving,” said Ambrose. Last week he enjoyed a cruise off the coast of the UK with his wife, Sue.

The results of the trial show the immunotherapy combination enjoyed a particularly high success rate in a group of patients whose tumours had high levels of an immune marker called PD-L1.

Survival rates in those with high levels of PD-L1 who received the immunotherapy cocktail were the highest ever reported in a firstline therapy trial of relapsed or metastatic head and neck cancer.

These patients lived an average of three months longer than those having chemotherapy. The median overall survival for these patients was 17.6 months, the highest average ever reported in this group of patients.

Researchers said they hoped future findings from the CheckMate 651 trial, funded by Bristol Myers Squibb, will show further benefits of the therapy in patients with advanced head and neck cancers.

“Despite the lack of statistical significance, these results are clinically meaningful,” said Prof Kevin Harrington, professor of biological cancer therapies at the ICR and consultant clinical oncologist at the Royal Marsden, who led the CheckMate 651 trial. “We will need to do longer follow-up to see whether we can demonstrate a survival benefit across all patients in the trial.”


Andrew Gregory Health editor

The GuardianTramp

Related Content

Article image
NHS England announces large-scale trial of potential early cancer test
More than 100,000 volunteers aged between 50 and 77 sought to take part in Galleri blood screening

Ian Sample Science editor

13, Sep, 2021 @5:00 AM

Article image
NHS preparing to offer ‘game-changing’ cancer treatment
Health service chief calls for affordable access to CAR-T, which modifies immune system to destroy cancer cells

Sarah Boseley Health editor

26, Apr, 2018 @5:29 PM

Article image
Woman whose NHS cancer trial was halted seeks to buy drug privately
Psychologist was due to get life-saving NHS cancer treatment until coronavirus struck

Denis Campbell Health policy editor

05, Jul, 2020 @11:01 PM

Article image
'Gamechanging' cancer drug rejected for use on NHS
Nivolumab deemed too expensive for the benefits but cancer specialists urge NHS and manufacturers to reach compromise

Sarah Boseley Health editor

11, Apr, 2017 @5:01 AM

Article image
AI software may help spot early signs of oesophageal cancer
Software in use at an NHS trust could prove a breakthrough in diagnosing one of the deadliest forms of cancer

Denis Campbell Health policy editor

01, Jul, 2021 @11:58 AM

Article image
Trial to test if cannabis-based mouth spray can treat brain tumours
First such study in the world aims to find out if Sativex combined with chemotherapy can help treat glioblastoma

Denis Campbell Health policy editor

03, Aug, 2021 @5:00 AM

Article image
Specialist centres could boost ovarian cancer survival rates – study
Researchers say improvement would not require new treatments but rather the optimal use of current techniques

Rachel Pugh

13, Jul, 2016 @2:44 PM

Article image
500,000 Britons a year will be diagnosed with cancer by 2035, study shows
Charity calls for urgent plan to secure future of oncology services amid fears predicted rise could stretch NHS to limit

Denis Campbell Health policy editor

11, Oct, 2016 @11:01 PM

Article image
Lung cancer blood test for smokers goes on trial

Tests will be carried out on 10,000 patients identified as having a higher risk of developing disease

Barry Neild

23, Mar, 2012 @1:49 AM

Article image
More foreign holidays will mean more skin cancer, scientists predict
A 78% increase in non-melanoma skin cancer may see the cost to the NHS of treating the disease rise to £465m a year by 2025

Denis Campbell Health policy editor

08, Dec, 2016 @7:29 PM